Drug Master File for Glioblastoma Therapy Product Filed with FDA
Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine injection)
Activities Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product TLX250-CDx
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings Corp
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for TLX591
Telix AGM – Chairman and CEO Addresses
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing site.